Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-Related Survival.

Peri-ICI SARS-CoV-2 mRNA vaccination within 100 days is not linked to longer progression-free or overall survival in USA tertiary cancer-center cohorts during periods of broad vaccine availability.

• Why it matters: Reported survival advantages from peri-ICI vaccination may reflect a treatment-synergy mechanism, but real-world confounding and selection bias could explain apparent benefits.
• What they did: Using an independent real-world cohort and a re-analysis of a published cohort from USA tertiary cancer centers, investigators applied a prior analytic framework across early-pandemic versus broad-uptake periods.
• The result: Longer survival seen early in the pandemic was not sustained when vaccines were widely available, was not specific to ICI therapies, and progression-free survival was not longer, indicating selection bias explains the earlier advantage.

AI summary of the abstract · may contain errors · not medical advice · read the paper.